Erudio Healtherudio.com
Sponsor
Canadian Cancer Trials Group trials: what clinicians said in public
An HCP commentary report on 1 clinical trial sponsored by Canadian Cancer Trials Group: PLATON. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 12 more trials with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (Canadian Cancer Trials Group). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| PLATON NCT03784755 · Canadian Cancer Trials Group | hormone sensitive oligometastatic prostate cancer | Not applicable | 445 | 31 | Deep | Nov 1, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| BR.31 NCT02273375 · Canadian Cancer Trials Group DeepView → | completely resected early-stage non-small cell lung cancer | Phase 3 | Deep | View | |||
| TRIPLE-SWITCH NCT06592924 · Canadian Cancer Trials Group DeepView → | metastatic castration-sensitive prostate cancer with suboptimal PSA response | Phase 3 | Deep | View | |||
| PR.21 NCT04663997 · Canadian Cancer Trials Group DeepView → | PSMA-positive metastatic castration-resistant prostate cancer | Phase 2 | Deep | View | |||
| IND.227 NCT02784171 · Canadian Cancer Trials Group DeepView → | untreated advanced malignant pleural mesothelioma | Phase 2/Phase 3 | Deep | View | |||
| CURB2 NCT06686771 · Canadian Cancer Trials Group DeepView → | metastatic non-small-cell lung cancer with oligoprogression | Phase 3 | Deep | View | |||
| BR.36 NCT04093167 · Canadian Cancer Trials Group DeepView → | non-small cell lung cancer | Phase 2/Phase 3 | Deep | View | |||
| NEO-RT NCT06205485 · Canadian Cancer Trials Group StandardView → | early rectal cancer | Phase 3 | Standard | View | |||
| PR.19 NCT02960087 · Canadian Cancer Trials Group StandardView → | localized prostate cancer | Not applicable | Standard | View | |||
| CCTG BL.13 NCT03768570 · Canadian Cancer Trials Group FocusedView → | muscle-invasive bladder cancer | Phase 2 | Focused | View | |||
| HN.13 NCT06641791 · Canadian Cancer Trials Group FocusedView → | advanced head and neck cancer | Phase 3 | Focused | View | |||
| SHAPE NCT01658930 · Canadian Cancer Trials Group FocusedView → | low-risk early-stage cervical cancer | Not applicable | Focused | View | |||
| CCTG BL12 NCT02033993 · Canadian Cancer Trials Group FocusedView → | Not given | Phase 2 | Focused | View | |||